Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern

Cancer Research

Volumn 65, Issue 3, 2005, Pages 1063-1070

  Li, Qiao ^a,b   Carr, Abbey L ^a   Donald, Elizabeth J ^a   Skitzki, Joseph J ^a   Okuyama, Ryugi ^a   Stoolman, Lloyd M ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DEPLETION; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG SYNERGISM; FEMALE; FIBROSARCOMA; INTERLEUKIN-12; INTERLEUKIN-18; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NF-KAPPA B; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 13444249480     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. + tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-58.
2. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunoth 1992;12:1-12.
3. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997;159:664-73.
4. Dobrzanski MJ, Reome JB, Dutton RW. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 1999;162:6671-80.
5. Nakajima C, Uekusa Y, Iwasaki, et al. A role of interferon-γ in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice. Cancer Res 2001;61:3399-405.
6. Segal JG, Lee NC, Tsung YL, Norton JA, Tsung K. The role of IFN-γ in rejection of established tumors by IL-12: source of production and target. Cancer Res 2002;62:4696-703.
7. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003;21:884-90.
8. Zhu LX, Sharma S, Gardner B, et al. IL-10 mediates sigma receptor-dependent suppression of antitumor immunity. J Immunol 2003;170:3585-91.
9. Halak BK, Maguire HC, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999;59:911-7.
10. Igietseme JU, Ananaba GA, Bolier J, et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol 2000;164:4212-9.
11. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003;63:2150-7.
12. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991;147:729-37.
13. Yoshizawa H, Chang AE, Shu S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2 activated tumor draining lymph node cells. Cancer Res 1992;52:1129-36.
14. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997;15:796-807.
15. Li Q, Yu B, Grover A, Zeng X, Takeshita N, Chang AE. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunoth 2002;25:304-13.
16. Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE. Polarization effects of 4-IBB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res 2003;63:2546-52.
17. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998;160:3444-52.
18. Chirathaworn C, Kohlmeier JE, Tibbetts SA, Rumsey LM, Chan MC, Benedict SH. Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J Immunol 2002;168:5530-7.
19. Li Q, Furman SA, Bradford CA, Chang AE. Expanded tumor-reactive CD4+ T cells responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res 1999;5:461-9.
20. Hart-Meyers J, Ryu A, Monney L, et al. Cutting Edge: CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions. J Immunol 2002;169:5382-6.
21. Hou W, Wu Y, Sun S, et al. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol 2003;170:1728-36.
22. Hodge JW, Sabzevari H, Yafal A, Gritz L, Lorenz M, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7.
23. Kemp R, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001;167:6497-502.
24. Tatsumi T, HuangJ, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003;63:6378-86.
25. Son Y, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res 2001;61:884-8.
26. Baxevanis CN, Gritzapis AD, Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 2003;171:2953-9.
27. Leung BP, Culshaw S, Gracie JA, et al. A role for IL-18 in neutrophil activation. J Immunol 2001;167:2879-86.
28. Barth RJ, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990;144:1531-7.
29. Skitzi J, Craig RA, Okuyama R, Knibbs RN, McDonagh K, Chang AE, Stoolman LM. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 2004;64:2183-91.
30. Fujihara SM, Cleaveland JS, Grosmaire LS, et al. A d-amino acid peptide inhibitor of NF-κB nuclear localization is efficacious in models of inflammatory disease. J Immunol 2000;165:1004-12.
31. Smyth MJ, Taniguchi M, Street S. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000;165: 2665-70.
32. Halin C, Gafner V, Villani ME, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor. Cancer Res 2003;63:3202-10.
33. Osaki T, Peron JM, Cai Q, et al. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ-and IL-12-independent antitumor effects. J Immunol 1998;160: 1742-9.
34. Wang SZ, Bao YX, Rosenberget CL, Tesfaigzi Y, Stark JM, Harrod KS. IL-12 and IL-18 modulate inflammatory and immune responses to respiratory syncytial virus infection. J Immuno 2004;173:4040-9.
35. Tatsumi T, Gambotto A, Robbins PD, Storkus WJ. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res 2002;62:5853-8.
36. Ju DW, Tao Q, Lou G, et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 2001;61:3735-40.
37. Grilli M, Chiu J, Lenardo MJ. NF-κB and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993;143:1-62.
38. Muller JM, Ziegler-Heitbrock H, Baeuerle PA. Nuclear factor κB, a mediator of lipopolysaccharide effects. Immunobiol 1993;187:233-56.
39. Corn RA, Aronica MA, Zhang F, et al. T cell-intrinsic requirement for NF-κB induction in postdifferentiation IFN-γ production and clonal expansion in a Th1 response. J Immunol 2003;171:1816-24.
40. Mukai S, Kjaergaard J, Shu S, Plautz GE. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 1999;59:5245-9.